COVID-19-Associated Pulmonary Aspergillosis in the Critical Care Setting

This article was originally published here

AACN Adv Crit Care. 2021 Dec 15;32(4):398-403. doi: 10.4037/aacnacc2021226.


The first confirmed case of COVID-19 in the United States was reported on January 20, 2020. Most infected individuals experience a mild illness with loss of taste and smell, body aches, fatigue, cough, and fever. However, about 5% of patients become critically ill and experience more serious symptoms such as respiratory distress, pulmonary emboli, or even multisystem organ failure. Those who become critically ill with COVID-19 are at high risk for superinfections, including pulmonary, bloodstream, and urinary tract infections. Invasive aspergillosis is emerging as a serious secondary pulmonary infection in patients with COVID-19 who experience respiratory distress syndrome. If these patients are not accurately diagnosed and subsequently treated, the infection can be fatal. This case study describes COVID-19-associated pulmonary aspergillosis in the critically ill patient.

PMID:34879133 | DOI:10.4037/aacnacc2021226